PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.73%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
522.30%
G&A growth while AGEN reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
3069944.64%
Other expenses change of 3069944.64% while AGEN maintains costs. Bruce Berkowitz would investigate efficiency.
230.56%
Operating expenses growth while AGEN reduces costs. John Neff would investigate differences.
230.56%
Total costs growth while AGEN reduces costs. John Neff would investigate differences.
243.75%
Interest expense growth above 1.5x AGEN's 3.67%. Michael Burry would check for over-leverage.
418.75%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
-202.01%
EBITDA decline while AGEN shows 1.29% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-230.56%
Operating income decline while AGEN shows 6.87% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-494.03%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-176.90%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-100.18%
Both companies reducing tax expense. Martin Whitman would check patterns.
-176.90%
Net income decline while AGEN shows 5.04% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
89.62%
EPS growth exceeding 1.5x AGEN's 4.35%. David Dodd would verify competitive advantages.
89.62%
Diluted EPS growth exceeding 1.5x AGEN's 4.35%. David Dodd would verify competitive advantages.
2567.99%
Share count reduction below 50% of AGEN's 0.62%. Michael Burry would check for concerns.
2567.99%
Diluted share reduction below 50% of AGEN's 0.62%. Michael Burry would check for concerns.